CrO Biosciences announced Laura A. Jones as President. Jones will focus on leading global regulatory strategic development, oversight of regulatory operations, clinical operations and R&D systems implementation strategies.
Beyond leadership expansion, CrO Biosciences is looking forward to increasing our staff of regulatory, clinical and quality personnel. Tamika Jackson will continue in her role as Chief Executive Officer and Chairwoman of the Board with an increased focus on business opportunities and the expansion of the firm's leadership team. Sasha El Castro will retain her role as Chief Financial Officer and Vice Chairwoman of the Board and continue to oversee business operations within the company.
"We are extremely pleased to welcome Laura to our executive team. She is the right leader for CrO Bio; Laura's extensive Research and Development background and business development skills will help CrO strengthen partnerships, develop strategic alliances and expand our sales presence," Jackson said.
Jones has 25 years of experience in Information Systems, supporting a wide array of technologies as well as 21 concurrent years of Pharmaceutical and Biotechnology Regulatory experience. She also has extensive knowledge of global agency guidance/regulations with a specialty in electronic submissions and submission management such as IND, BLA, MAA submissions systems, EDMS content management systems and integration. Laura has a wealth of knowledge and experience. She was also awarded the distinguished recognition award from the FDA for Electronic Submissions Gateway (ESG) pilot test group participation.